Clinical Trials Logo
  1. Home
  2. Muscle Invasive Bladder Cancer
  3. NCT04099589

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Muscle-invasive Bladder Cancer Clinical Trial

Official title:
Multicenter Phase II Study of Gemcitabine/Cisplatin (GC) Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) in the Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Clinical Trial Summary

Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies showed this neoadjuvant treatment model might benefit patients. So This prospective Phase II clinical trial was designed to explore the efficacy of chemotherapy combined with PD-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive bladder urothelial carcinoma, then to improve the rate of complete pathological remission, survival and provide medical evidence.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04099589
Study type Interventional
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Jianzhong Shou
Phone 86-18813019104
Email chuanzhenc@yeah.net
Status Recruiting
Phase Phase 2
Start date October 1, 2019
Completion date October 1, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04687254 - Gender-related Characteristics of Bladder Cancer Treatment
Active, not recruiting NCT03661320 - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Phase 3
Active, not recruiting NCT02462239 - Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging N/A
Recruiting NCT04660344 - A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy Phase 3
Withdrawn NCT03832673 - Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study Phase 2
Recruiting NCT06373055 - Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Recruiting NCT06335667 - mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer N/A
Terminated NCT03234153 - Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin Phase 2
Recruiting NCT05945108 - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting NCT06362330 - Multi-parametric MRI in Patients of Bladder Cancer
Completed NCT04209114 - A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Phase 3
Active, not recruiting NCT00808639 - Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Phase 2